My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
BSE: 500674 | NSE: SANOFI | Pharmaceuticals & Drugs | Small Cap
1. Is Sanofi India Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Sanofi India Ltd is a good quality company.
2. Is Sanofi India Ltd undervalued or overvalued?
The key valuation ratios of Sanofi India Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
3. Is Sanofi India Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Sanofi India Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | TTM | |||
| ROCE % ⓘ | 19.1% | 15.5% | 16.9% | 17.3% | 16.5% | 17.8% | 19.6% | 22.4% | 27.5% | 30.2% | - | ||
| Value Creation Index ⓘ | 0.4 | 0.2 | 0.3 | 0.3 | 0.2 | 0.3 | 0.5 | 0.7 | 1.0 | 1.2 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 1,809 | 1,977 | 2,193 | 2,367 | 2,464 | 2,771 | 3,071 | 2,902 | 2,957 | 2,770 | 2,800 | ||
| YoY Gr. Rt. % | - | 9.3% | 10.9% | 7.9% | 4.1% | 12.5% | 10.8% | -5.5% | 1.9% | -6.3% | - | ||
| Adj EPS ⓘ | 105.4 | 95.4 | 114.3 | 131.3 | 139.9 | 163.5 | 197.9 | 220.9 | 259.2 | 229.4 | 248.6 | ||
| YoY Gr. Rt. % | - | -9.5% | 19.8% | 14.9% | 6.6% | 16.8% | 21.1% | 11.6% | 17.4% | -11.5% | - | ||
| BVPS (₹) ⓘ | 580.3 | 643.7 | 707.3 | 810.7 | 869.9 | 950.2 | 1,043.5 | 897.8 | 941.5 | 527.7 | 609.6 | ||
| Adj Net Profit ⓘ | 243 | 220 | 263 | 302 | 322 | 377 | 456 | 509 | 597 | 528 | 573 | ||
| Cash Flow from Ops. ⓘ | 273 | 265 | 213 | 322 | 435 | 374 | 412 | 611 | 559 | 399 | - | ||
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | 4.9% | 2.4% | -3.4% | -6.3% | ||||||||
| Adj EPS ⓘ | 9% | 10.4% | 5% | -11.5% | ||||||||
| BVPS ⓘ | -1.1 | -9.5 | -20.3 | -44 | ||||||||
| Share Price | 10.8% | 6.3% | -4% | 5.1% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | TTM | ||
| Return on Equity % ⓘ | 19 | 15.5 | 16.9 | 17.2 | 16.5 | 17.7 | 19.6 | 22.3 | 27.5 | 30.2 | 43.7 | |
| Op. Profit Mgn % ⓘ | 22 | 17.3 | 21 | 22.6 | 21.9 | 22.6 | 21.7 | 24.7 | 25.8 | 25.4 | 26.4 | |
| Net Profit Mgn % ⓘ | 13.4 | 11.1 | 12 | 12.8 | 13.1 | 13.6 | 14.9 | 17.5 | 20.2 | 19.1 | 20.5 | |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | |
| Working Cap Days ⓘ | 122 | 151 | 149 | 156 | 287 | 379 | 386 | 419 | 436 | 470 | 0 | |
| Cash Conv. Cycle ⓘ | 38 | 42 | 39 | 50 | 31 | 20 | 18 | 13 | 2 | 1 | 0 | |
Return on Equity has increased versus last 3 years average to 43.70%
Sales growth has been subdued in last 3 years -3.37%
Net Profit has been subdued in last 3 years 5.03%
Sales growth is not so good in last 4 quarters at -4.46%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 248.6 | 67.7 |
| TTM Sales (₹ Cr.) | 2,800 | 743 |
| BVPS (₹.) ⓘ | 609.6 | 0 |
| Reserves (₹ Cr.) ⓘ | 1,381 | 413 |
| P/BV ⓘ | 11.56 | 0.00 |
| PE ⓘ | 28.35 | 104.14 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 5240.00 / 7230.55 |
| All Time Low / High (₹) | 235.05 / 9300.00 |
| Market Cap (₹ Cr.) | 16,231 |
| Equity (₹ Cr.) | 23 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 38.1 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Sanofi India is one of the entities through which Sanofi operates in India. It was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited. Over the years, its name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India Limited, Hoechst Marion Roussel Limited and Aventis Pharma Limited. Sanofi, one of the world's leading healthcare companies, and its 100% subsidiary - Hoechst GmbH, are the major shareholders of Sanofi India Limited and together hold 60.4% of its paid-up share capital. The shares of Sanofi India Limited are quoted on the Bombay Stock Exchange and the National Stock Exchange. The company has two manufacturing sites in Ankleshwar and Goa. Sanofi India also manufactures its products through third party manufacturers. The different types of dosage forms include tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams and ointments. These products are manufactured in accordance with the same quality standards as those prevalent at its own manufacturing sites for domestic consumption and for export to Russia, the Ukraine and other CIS countries.
Business area of the company
The company is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. The company prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. The company stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
Products
Pharmaceutical products (Adenocor, Aldurazyme, AllStar, Amaryl, Apidra, Arava, Aubagio, Augeoz, Brodactam, Cardace, Caspercid, Cerezyme, Cetapin, Clexane, Cordarone, Daonil, Depakote, Fabrazyme, Fasturtec, Fludara, Frisium, Insuman, Jevtana, Lantus, Lasilactone, Lasix, Lyxumia, Metosan, M-Nem, Myoril, Myozyme, Plavix, Primacor, Renvela Sachets, Soframycin, Solian, Stilnoct, Synvisc, Targocid, Taxotere, Telsite, Thymoglobuline, Thyrogen, Toujeo, Trental, Valparin, Vinlep, Zemiglo).
Vaccines (Adacel, Avaxim, FluQuadri, Hexaxim, Imovax Polio, Menactra, Pentaxim, Shan5, Shanchol, ShanIPV, ShanTT, Shanvac-B, Stamaril, Vaxigrip)
Consumer Healthcare products (Allegra, Allegra, Allegra M, Aminofit Forte, Amino-fit, Avil, Baralgan NU, Berrycran, Buscogast, Cetgel, Collaflex, Combiflam Plus, Combiflam Suspension, Combiflam IcyHotTM, Combiflam IcyHotTM spray, CoQ 300, DePURA by Sanofi, Dulcoflex Natural, DulcoSoft Sachet, E-Cod Plus, E-Cod W, Enlarge Forte, Enterogermina, Estoven XT, Festal N, FreeFlex Forte, Icegel, Lactacyd, Macraberin M, Mega FreeFlex, Multivite Gold, Multivite Woman, Multivite CD,
Multivite-FM Omega, Novalgin NU, Phospholip TF, Primosa, Radiance H, Seacod Active, Selace Forte,
Triomega)
Milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Download APP
